You are here

HBI-002 to Treat Ulcerative Colitis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DK123933-01A1
Agency Tracking Number: R41DK123933
Amount: $219,112.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 300
Solicitation Number: PA19-270
Timeline
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-05-16
Award End Date (Contract End Date): 2021-10-31
Small Business Information
2029 VERDUGO BLVD #125
Montrose, CA 91020-1626
United States
DUNS: 078631704
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 EDWARD GOMPERTS
 (818) 445-5890
 jade818@charter.net
Business Contact
 ANDREW GOMPERTS
Phone: (858) 232-9495
Email: agomperts@hillhurstbio.com
Research Institution
 BETH ISRAEL DEACONESS MEDICAL CENTER
 
330 BROOKLINE AVENUE
BOSTON, MA 02215
United States

 Domestic nonprofit research organization
Abstract

PROJECT SUMMARY
There is an urgent need for the development of new approaches to treat patients suffering from Ulcerative
Colitis (UC), which is estimated to impact approximately one million adults in the United States, leading to
morbidity, heightened risk of cancer, and mortality. In multiple preclinical studies, we and others have defined
the therapeutic potential of low-dose exogenous carbon monoxide (CO) in UC, including in simultaneously
reducing inflammation, promoting tissue repair, and limiting pathogenic bacterial infection.
To date, inhaled CO gas (iCO) and CO bound to carrier molecules (CORMs) have been the modalities of
choice in the majority of animal and in all the clinical studies. However, iCO and CORMS are not expected to
be pharmaceutically acceptable and viable chronic therapeutic options due to, with iCO, the risk of inadvertent
exposure from the presence of compressed CO cylinders as well as difficulties in controlling dosing and, with
CORMs, carrier molecule toxicology, stability, and CO release characteristics that have proven to be a
substantial barrier to development. The objective of the proposed project is to investigate HBI-002, a novel oral
or rectally administered CO drug product that was developed to enable the chronic use of CO in UC.
The safety and tolerability of CO has been demonstrated in five successful Phase 1 clinical studies supported
by well-defined preclinical data sets that led to approval by the FDA for human testing. HBI-002 comprises an
oral formulation containing precise amounts of CO that are not bound to a carrier molecule (i.e. not a CORM)
and efficiently absorbed from the gastrointestinal tract. Preclinical in vivo pharmacokinetic and
pharmacodynamic studies demonstrated proof-of-concept feasibility, tolerability, and bioavailability. The next
step in development is to demonstrate that HBI-002 is effective in clinically relevant animal models of UC as
has been shown with other forms of CO and to better understand the potential mechanism(s) of action. Based
upon the substantial literature of CO in IBD, our central hypothesis that will be tested in this project is: HBI-002
will modulate the immune response to regulate inflammation, improve survival, and promote healing in
UC mouse models.PROJECT NARRATIVE
This proposal is intended to support research evaluating whether HBI-002, an oral or rectal carbon monoxide
(CO) therapeutic, can improve outcomes in animal models of Ulcerative Colitis (UC). If successful, the project
will provide proof-of-concept for further development of HBI-002 in UC as a promising therapeutic to improve
outcomes in this devastating condition.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government